Biotia

Biotia is a health-tech company located in New York, NY, that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Our mission is to fight infectious diseases by deploying the leading reference library of microbes worldwide. As of 2020, Biotia was accredited as a fully operational CLEP and high complexity CLIA-certified laboratory by the NY State Department of Health. We are fortifying local labs in diagnostic deserts with modern sequencing technology and training to leapfrog legacy diagnostics. Using BIOTIA-DX you can identify organisms with a clinically validated metagenomics tool that is more sensitive than culture or qPCR. BIOTIA-ID is a comprehensive genomics-based assay with extensive clinical validation and pending regulatory approval. With BIOTIA-ID Urine, we have resolved these problems, designed and clinically validated a novel diagnostic assay with high sensitivity, specificity, and extensive characterization for a variety of different disease causing pathogens. Biotia presented together wtih the World Health Organziation (WHO), the Pasteur Institute, and Fiocruz, warning that while we are witnessing the dismantling of essential infectious disease monitoring programs, we expect infectious disease threats to increase, at least partially driven by climate change, changes in land use, and global travel.